{
  "docId": "019de074-15c9-703f-ba69-83bd63385db9",
  "docSlug": "61dc585c6c50f6919636d426c025da60",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 42 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 35,
  "pageCount": 42,
  "prevPage": 34,
  "nextPage": 36,
  "slideType": "customer_journey",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a patient journey/treatment pathway framework to map current standard of care against emerging therapeutic interventions.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de074-15c9-703f-ba69-83bd63385db9/35",
  "deckHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9",
  "deckJsonHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9.json",
  "deckAnchorHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9#slide-35",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.96,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Treatment pathway from Early to Metastatic 3L+ stages",
      "attrs": null,
      "subkind": "customer-journey",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3ed50a3e-8e4c-4cb9-b4f1-3d629304c95c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.96,
        "x": 0.03,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "HR = hormone receptor; ET = endocrine therapy; CDK4/6i = cyclin-dependent kinase 4/6 inhibitors; HRD = homologous recombination deficiency; gBRCAm = breast cancer gene mutation; ER = oestrogen receptor; AI = aromatase inhibitors; HER2 = human epidermal growth receptor 2; Dato-DXd = datopotomab deruxtecan.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8327822f-6008-44d1-9e06-19795cb49d2d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.78,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "Camizestrant ngSERD, capivasertib extending ET in ER-driven disease",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "97e91a21-9ee5-4e25-b7fe-168f5ea7c085",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.47,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "Reshaping HR+ Breast Cancer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a8458644-4969-4bde-9d1c-1b13f3e3bda8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Customer journey map",
      "slug": "customer-journey-map",
      "agent": null,
      "layer": "slide",
      "matchId": "b32a556f-d8ab-4856-8331-27a7354201a3",
      "evidence": "diagram/customer-journey: Treatment pathway from Early to Metastatic 3L+ stages",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "customer-journey-map",
      "slug": null,
      "matchId": "caf72682-c071-4a0e-9d27-d95998490c4a",
      "evidence": "The slide maps the progression of breast cancer treatment from early stages through metastatic lines of therapy.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 37,
      "from": 30,
      "beatId": "88b7703b-c29f-499c-87c5-dd04e5a0e55a",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "Other key data, Enhertu, and capivasertib",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 36,
      "from": 34,
      "name": "Confession",
      "slug": "22-confession",
      "bestFor": "Crisis communication, rebuilding trust, authenticity marketing",
      "matchId": "b58a08dc-4e91-457f-a2e1-8907740ea80a",
      "evidence": "Problem statement and customer journey",
      "position": 0,
      "objective": "What is the significant unmet need in breast cancer?",
      "structure": "The Honest Admission -> What We Learned -> How We're Different Now",
      "confidence": 0.7,
      "description": "Build credibility by admitting a weakness or mistake before presenting your strength"
    },
    {
      "to": 36,
      "from": 35,
      "name": "Voice Of Customer",
      "slug": "51-voice-of-customer",
      "bestFor": "Product strategy, customer experience, market research",
      "matchId": "e11ba950-46fd-416a-b7b0-47f302af001d",
      "evidence": "Customer journey and problem statement",
      "position": 3,
      "objective": "What are the needs of patients with HR+ Breast Cancer?",
      "structure": "What Customers Say (Verbatim) -> The Pattern Across Voices -> The Insight -> The Response",
      "confidence": 0.6,
      "description": "Let customer quotes and feedback drive the narrative and validate the insight"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}